<DOC>
	<DOCNO>NCT00146614</DOCNO>
	<brief_summary>The purpose study determine incidence Graft v . Host Disease ( GVHD ) non-myeloablative transplantation reduce use combination three immune suppressive medication ; sirolimus , tacrolimus methotrexate .</brief_summary>
	<brief_title>Tacrolimus , Sirolimus Methotrexate Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation</brief_title>
	<detailed_description>- Patients admitted hospital receive chemotherapy stem cell transplant ( SCT ) . The total duration hospitalization procedure approximately 8 day . Once admitted patient receive fludarabine daily 4 day , busulfex daily 4 day . Two day chemotherapy end , patient receive infusion donor cell . - Just prior transplant follow transplant , patient receive sirolimus ( orally ) , tacrolimus ( orally ) low dos methotrexate ( chemotherapy ) . Methotrexate give day 1,3 6 transplant . - Sirolimus taper begin week 9 transplant evidence GVHD eliminate week 26 clinically feasible . - Tacrolimus taper begin week 9 transplant evidence GVHD eliminate week 26 clinically feasible . - Patients also receive medication help prevent possible infection . - After stem cell infusion , patient examine blood test weekly 1 month . At 1 month visit , bone marrow biopsy perform look evidence donor cell bone marrow . After one month evaluation patient examine every 2 week repeat bone marrow perform 3-4 month transplant .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients hematologic malignancy high risk complication conventional transplantation . Donors ( relate unrelated ) identical 6 HLA locus . Age great 18 ECOG Performance Status 02 Life expectancy great 100 day . Pregnancy Evidence HIV infection Heart failure uncontrolled medication Total Bilirubin &gt; 2.0mg/dl due hepatocellular dysfunction AST &gt; 90 Serum creatinine &gt; 2.0 Cholesterol &gt; 300 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Graft versus Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
</DOC>